Filed 2mo ago· Mar 12, 2026
28 days to disclose
Julia Letlow
RHouseLouisiana-05
↑bought
Regeneron Pharmaceuticals
REGN
$1K-$15K
−3.2% vs S&P 500
Trade dateFeb 12, 2026
Common Stock
Stock trades that members of the U.S. House and Senate disclose, by law, after they buy or sell. Pulled straight from the official government websites — typically posted within hours of being filed.












| Filed | Politician | Type | Stock | Trade date | Smart move? | Size |
|---|---|---|---|---|---|---|
Mar 12, 2026 2mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | Regeneron Pharmaceuticals REGN Common Stock | Feb 12, 2026 28 days to disclose | Bad buy·−$639-8.0% −3.2% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | AstraZeneca AZN Depositary Shares | Dec 8, 2025 36 days to disclose | Good buy·+$103+1.3% +3.2% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↓sold | AbbVie ABBV | Dec 8, 2025 36 days to disclose | Flat·+0.0% −1.9% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | AbbVie ABBV | Apr 28, 2025 260 days to disclose · 215 past 45-day window | Good buy·+$1.1K+13.7% +6.5% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↓sold | Bristol-Myers Squibb BMY Common Stock | Apr 28, 2025 260 days to disclose · 215 past 45-day window | Flat·+0.0% +7.2% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↓sold | AbbVie ABBV | Jan 24, 2025 354 days to disclose · 309 past 45-day window | Flat·+0.0% +2.9% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↓sold | Amgen AMGN | Nov 19, 2024 420 days to disclose · 375 past 45-day window | Flat·+0.0% +5.2% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | AbbVie ABBV | Oct 23, 2024 447 days to disclose · 402 past 45-day window | Good buy·+$1.3K+16.4% +17.6% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | Bristol-Myers Squibb BMY Common Stock | Oct 23, 2024 447 days to disclose · 402 past 45-day window | Good buy·+$245+3.1% +4.3% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | Pfizer PFE Pfizer, Inc. | Oct 23, 2024 447 days to disclose · 402 past 45-day window | Bad buy·−$646-8.1% −6.8% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | Amgen AMGN | Oct 23, 2024 447 days to disclose · 402 past 45-day window | Good buy·+$402+5.0% +6.3% vs S&P 500 | $1K-$15K midpoint $8K |
Jan 13, 2026 4mo ago | ![]() Julia Letlow RHouseLouisiana-05 | ↑bought | Vertex Pharmaceuticals VRTX - | Oct 23, 2024 447 days to disclose · 402 past 45-day window | Bad buy·−$826-10.3% −9.1% vs S&P 500 | $1K-$15K midpoint $8K |